AgomAb Therapeutics

Agomab Therapeutics is a biotechnology company specializing in the development of novel treatments. The company's primary focus is on preserving and restoring organ function in fibrotic diseases. Agomab Therapeutics operates from multiple locations, including Antwerpen, Belgium; A Coruña, Spain; and Cambridge, Massachusetts, USA. Agomab Therapeutics leverages its expertise in growth factor biology to develop treatments. These treatments aim to resolve fibrosis, repair tissue structure, and restore organ function. The company's pipeline targets key signaling pathways such as TGFβ and HGF. Agomab Therapeutics' target industries include Healthcare, Pharmaceuticals, and Biotechnology. The company's competitive advantages include deep expertise in growth factor biology, an innovative R&D approach, an ambitious corporate strategy, a strong scientific foundation, and a broad clinical pipeline. The company is led by a team including Tim Knotnerus as Chief Executive Officer, Philippe Wiesel as Chief Medical Officer, Andrea Sáez as Chief Development Officer, Pierre Kemula as Chief Financial Officer, Paul van der Horst as Chief Business Officer, and Ellen Lefever as General Counsel. The Chairman of the Board is David Epstein. The board also includes Non-Executive Directors Angelika Jahreis and Colin Bond, who also serves as Chairman of the Audit Committee. Felice Verduyn – van Weegen represents EQT Life Sciences, Ming Fang represents Redmile, and Ohad Hammer represents Pontifax. Agomab Therapeutics is committed to transformative science, with a team driven by commitment and passion. The company is supported by experienced team members and leading partners and investors. Contact information includes phone number +32 3 318 91 70, and email addresses [email protected], [email protected], and [email protected].